Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
Ann Oncol
.
2018 Oct 1;29(10):2143.
doi: 10.1093/annonc/mdy261.
Authors
A K Krug
1
,
D Enderle
1
,
C Karlovich
2
,
T Priewasser
1
,
S Bentink
1
,
A Spiel
1
,
K Brinkmann
1
,
J Emenegger
1
,
D G Grimm
1
,
E Castellanos-Rizaldos
3
,
J W Goldman
4
,
L V Sequist
5
,
J-C Soria
6
,
D R Camidge
7
,
S M Gadgeel
8
,
H A Wakelee
9
,
M Raponi
2
,
M Noerholm
1
,
J Skog
10
Affiliations
1
Exosome Diagnostics GmbH, Martinsried, Germany.
2
Clovis Oncology Inc., San Francisco, USA.
3
Exosome Diagnostics, Waltham, USA.
4
University of California Los Angeles, Los Angeles, USA.
5
Massachusetts General Hospital, Boston, USA.
6
Institut Gustave Roussy, Villejuif, France; University Paris-Sud, Paris, France.
7
University of Colorado, Denver, USA.
8
Karmanos Cancer Institute/Wayne State University, Detroit, USA.
9
Stanford University, Stanford, USA.
10
Exosome Diagnostics, Waltham, USA. Electronic address:
[email protected]
.
PMID:
30060089
DOI:
10.1093/annonc/mdy261
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma, Non-Small-Cell Lung*
Circulating Tumor DNA*
ErbB Receptors / genetics
Humans
Lung Neoplasms*
Mutation
RNA
Substances
Circulating Tumor DNA
RNA
EGFR protein, human
ErbB Receptors